New implant as remedy for glaucoma
Glaucoma is a serious eye disease that affects three to five percent of the population over the age of 50, and is a condition that not infrequently results in blindness. The condition usually indicates that the eye pressure is (significantly) elevated. Eye drops and laser treatments usually work well, but surgical treatment is often indicated to get eye pressure permanently under control.
In severe cases, the insertion of a plastic implant is necessary. Although these implants often work well, a great deal of knowledge and skill is required for correct placement and intensive patient follow-up is a must; the risk of possible complications is fairly high and it can be difficult to predict the eye-pressure-lowering effect. This unpredictability and fear of complications means there is a great need for safe and standardized minimally invasive surgery, making it a more acceptable alternative for both surgeons and patients. In order to meet this need, a new and promising glaucoma implant has been developed under the leadership of the Maastricht UMC+ University Clinic for Ophthalmology and researchers at the Technical University of Eindhoven. The challenge for startup PEYEONEER MedTech, based at the Brightlands Maastricht Health Campus, is to get the glaucoma implant to patients.
Read the full article on the Brightlands website.
Also read
-
On 31 October 2024, the Globalisation & Law Network hosted a seminar featuring Dr Gesa Kübek, Assistant Professor in European Law at Groningen University.
-
Maastricht University is leading a research project funded by the Worldwide Universities Network, bringing together perspectives from four continents on green hydrogen policies.
-
With a consortium, she will research how early action and adaptation can effectively build on local at-risk populations’ resilience needs and strategies and how their knowledge can best be included in large-scale climate modelling to better reflect their needs.